Duzela

Quick links to important sections

Duzela

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Duzela

Property Description
Active Ingredient Duloxetine Hydrochloride
Form Delayed-Release Capsule (DR Capsule)
Pharmacological Class Selective Serotonin and Norepinephrine Reuptake Inhibitor (SNRI)
General Purpose Mood stabilization and management of chronic pain signals
Origin Synthetic (laboratory-derived)

What Type of Medicine is Duzela? (Identity and Classification)

Duzela is a synthetic, prescription-only medication whose active component is Duloxetine Hydrochloride. It is formally classified as a Selective Serotonin and Norepinephrine Reuptake Inhibitor (SNRI), meaning it acts systemically within the central nervous system. This classification indicates that the drug operates by influencing the balance of specific nerve-signaling chemicals in the body. Duloxetine's SNRI classification and its mechanism involve inhibiting the reuptake of both Serotonin and Norepinephrine. This dual-action structure defines its therapeutic profile.


Composition, Origin, and Delivery Form

The primary psychoactive compound in Duzela is the synthetic chemical Duloxetine Hydrochloride, supplied for oral administration as a Delayed-Release Capsule (DR Capsule). This specific design is necessary because the Duloxetine compound is acid-labile and would be destroyed by the acidic environment of the stomach before the body could absorb it. To ensure systemic absorption, Duloxetine is administered in an enteric-coated form. While Duzela is typically a single-ingredient drug, combination products, such as Duzela M, are available that integrate the nerve-supporting compound Methylcobalamin alongside Duloxetine, a feature specifically targeted towards patients needing nerve support.


General Therapeutic Purpose and Action

The overarching general purpose of this medicine is to help stabilize emotional balance and modulate signals of chronic discomfort by affecting nerve communication. The SNRI action achieves this by inhibiting the reuptake of Serotonin and Norepinephrine into nerve endings, increasing the availability of these messengers in the communication spaces between nerve cells. By sustaining higher concentrations of these molecules, the medication supports the central nervous system in managing chemical imbalances associated with persistent low mood, anxiety, and the perception of long-term nerve-related discomfort.

Regulatory References

  1. National Library of Medicine
  2. MedlinePlus Drug Information

What side effects are possible with Duzela?

Possible Side Effects and Safety Information

The safety profile of Duzela (Duloxetine Hydrochloride) is officially documented across several categories, reflecting data compiled from clinical studies and post-marketing surveillance, consistent with regulatory standards (e.g., FDA, EMA).

Side effects are classified by frequency and by the System-Organ Class (SOC) affected. The most frequently reported adverse reactions include those affecting the Gastrointestinal and Nervous Systems.

Frequency of Adverse Reactions

Frequency Classification Examples (as per regulatory labels)
Very Common (ge 1/10) Nausea, Headache, Dry Mouth
Common (ge 1/100 to < 1/10) Somnolence, Dizziness, Insomnia, Constipation, Hyperhidrosis
Uncommon (ge 1/1,000 to < 1/100) Orthostatic Hypotension, Seizures, Hyponatremia

Serious Adverse Reactions

Official labeling highlights the risk of Serious Adverse Reactions (SARs), including Hepatotoxicity and cases of Hepatic Failure, particularly when associated with chronic liver disease or substantial alcohol use. A formal regulatory warning exists regarding the increased risk of Suicidal Thoughts and Behaviors in pediatric and young adult patients up to 24 years of age. Other serious reactions documented include Serotonin Syndrome and Severe Skin Reactions.

Population-Specific Safety Considerations

Safety statements restrict use in specific populations. Duzela should be avoided in patients with severe renal impairment (CrCl <30 mL/min) or chronic liver disease/cirrhosis. Older adults may have an increased likelihood of falls and a greater risk of hyponatremia. Furthermore, cases of Orthostatic Hypotension and Syncope are reported, particularly at the initiation of treatment.

Overdose and Emergency Response

Overdose Manifestations and Complications

Overdose with Duloxetine (Duzela) is documented in regulatory sources as potentially affecting the central nervous, cardiovascular, and autonomic systems. Documented clinical manifestations may include seizures or convulsions, significant somnolence, drowsiness, and states of unresponsiveness progressing to coma. Cardiovascular signs often involve tachycardia and fluctuations in blood pressure. Other symptoms reported include vomiting and diarrhea.

The official prescribing information highlights the risk of severe, life-threatening outcomes, including the development of Serotonin Syndrome and Neuroleptic Malignant Syndrome (NMS)-like reactions. Fatal outcomes have been reported in the context of acute overdose in some clinical reports.

Emergency Actions and Management

Regulatory authorities mandate immediate action when overdose is suspected. Users must call the poison control helpline for guidance or immediately call emergency services (e.g., 911) if the affected individual collapses, has a seizure, is unresponsive, or has trouble breathing.

Management of Duloxetine overdose is focused strictly on supportive care. It is officially documented that no specific antidote is known. Treatment procedures require the provision of symptomatic and supportive treatment and continuous monitoring of cardiac and vital signs due to the risk of arrhythmia. Special caution is noted regarding increased systemic exposure and potential toxicity in patients with severe renal or chronic hepatic impairment.

Therapeutic Uses of Duzela

Duzela (Duloxetine) is commonly used to help manage symptoms across multiple relevant therapeutic areas, offering supportive relief for both emotional distress and chronic physical discomfort.

This medication is applied across domains where additional symptomatic support is needed, addressing core conditions such as Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and chronic pain syndromes, including Diabetic Peripheral Neuropathic Pain (DPNP), Fibromyalgia, and Stress Urinary Incontinence (SUI) in women.

It is used for managing symptom clusters that create noticeable physiological strain, such as persistent low mood and excessive worry.

In managing these varied manifestations, Duzela is relevant for easing symptoms related to heightened neurological or muscular activity, such as burning pain and widespread body aches, providing supportive relief when symptoms interfere with routine activities. The medication may assist with maintaining functional stability and helping to improve day-to-day comfort during symptomatic periods.


Quick Fact: Relief for Neuropathic Symptoms Duzela is commonly used to help manage the specific type of burning, tingling, or shooting pain associated with nerve damage, which represents symptoms distinct from general muscle discomfort.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who can and cannot use Duzela?

The official regulatory labeling defines specific populations who are eligible to use Duzela and those for whom it is contraindicated.

Contraindications and Non-Eligibility

Use is contraindicated in patients with uncontrolled narrow-angle glaucoma, severe hepatic impairment (liver disease), or severe renal impairment (creatinine clearance <30 mL/min). Patients must also not take Duzela if they are currently using a Monoamine Oxidase Inhibitor (MAOI), including linezolid or intravenous methylene blue, or within 14 days of stopping one.

Age-Related Eligibility

Duzela is approved for adults across all labeled indications. Pediatric use is restricted; it is approved only for Generalized Anxiety Disorder (GAD) in children aged 7 and older, and for Fibromyalgia in adolescents aged 13 and older. Safety and efficacy are not established for other indications or in younger children.

Conditional Use and Status

Use during pregnancy is generally not recommended unless the potential benefits outweigh the risks; late-pregnancy exposure requires monitoring of the neonate. Duloxetine is excreted in breast milk. Caution is advised for patients with pre-existing hypertension or a history of seizure disorder. The medicine should not be prescribed to patients with substantial alcohol use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Duzela (duloxetine) can interact with several types of medicines, potentially increasing the risk of serious side effects or altering drug concentrations.

Contraindicated Combinations

Monoamine Oxidase Inhibitors (MAOIs): Concomitant use with MAOIs, including psychiatric MAOIs (e.g., phenelzine) and other agents like Linezolid or intravenous Methylene Blue, is contraindicated due to the high risk of Serotonin Syndrome, a potentially life-threatening condition. A washout period of at least 14 days is required when switching between Duzela and an MAOI.

Clinically Significant Interactions

Serotonergic Agents: The use of Duzela with other serotonergic medicines (such as other SSRIs, SNRIs, triptans, tramadol, or the herbal supplement St. John's Wort) requires caution as it increases the risk of Serotonin Syndrome.

Drugs Affecting Hemostasis: Duzela may increase the risk of bleeding. Caution is necessary when co-administering with drugs that affect blood clotting, including Nonsteroidal Anti-inflammatory Drugs (NSAIDs), aspirin, and anticoagulants (e.g., warfarin).

Metabolic Inhibitors: Duzela is metabolized by liver enzymes CYP1A2 and CYP2D6. Co-administration with potent CYP1A2 inhibitors (e.g., fluvoxamine or certain quinolone antibiotics) should be avoided, as this significantly increases Duzela concentrations. Duzela itself is a moderate inhibitor of CYP2D6, which can increase the concentration of other drugs metabolized by that enzyme (e.g., desipramine, tolterodine).

Mechanism of Action

Dual Neurotransmitter Potentiation

Duzela's active component, Duloxetine, functions as a selective inhibitor of two key integral membrane proteins: the Serotonin Transporter (SERT) and the Norepinephrine Transporter (NET). By preventing the reuptake of the neurotransmitters Serotonin (5-HT) and Norepinephrine (NE), the drug sustains a higher extracellular concentration of both monoamines in the central nervous system synapses. This sustained increase in neurotransmitter density directly influences the strength and duration of nerve communication.


Central Modulation of Nociceptive Pathways

This neurochemical potentiation enhances the activity of the Descending Pain Inhibitory Pathways (DPIS), which modulate signal transmission from the brainstem to the spinal cord. The mechanism amplifies the nervous system's innate ability to suppress or dampen the transmission of signals in the spinal cord's dorsal horn. This central action results in a physiological consequence in how the nervous system processes signals.


Structural Support via Methylcobalamin (Duzela M)

In combination formulations, Methylcobalamin acts as a cofactor for the enzyme Methionine Synthase. This supports metabolic processes essential for the structural composition of nerves, specifically the synthesis and maintenance of the Myelin sheath. This structural mechanism operates alongside the functional, neurochemical modulation provided by Duloxetine.

Dosage and Administration Information

Duzela is an oral medication formulated as a Delayed-Release Capsule (DR Capsule). Standard administration requires that the capsule must be swallowed whole and not chewed, crushed, or opened to maintain the integrity of its enteric coating, which is essential for proper systemic absorption. The medicine is generally administered once daily and may be taken without regard to meals.


Official Administration Guidelines

Instruction Detail
Route of Administration Oral administration only.
Dosing Schedule The typical adult maintenance dose is 60 mg once daily for most approved indications. Starting doses are often 30 mg once daily for one week before increasing. The maximum daily dose is 120 mg for Major Depressive Disorder and Generalized Anxiety Disorder.
Special Handling Must be swallowed whole; not to be crushed or opened.
Timing May be taken with or without food.
Discontinuation Requires gradual dose reduction (tapering) upon cessation, as part of standard clinical practice.

Population-Specific Use

Administration is officially avoided in adult patients with severe hepatic impairment or severe renal impairment (creatinine clearance less than 30 mL/min). While no adjustment is based solely on age, a lower starting dose may be recommended for older adults with Generalized Anxiety Disorder to promote initial adjustment. The same principles of use define how the medicine is administered to pediatric patients for approved conditions.

Recent Clinical Evidence

Research evidence / Overview of studies for Duzela


Evidence Researching Emotional Disorders: MDD and GAD

Research examined symptom measures over time in individuals with Major Depressive Disorder (MDD). These studies were primarily short-term Randomized Controlled Trials (RCTs) that monitored changes on standardized symptom scales. Research also examined patients with MDD who experienced co-occurring outcomes related to physical discomfort. Findings describe patterns observed in these studies related to measurements of symptom response. Long-term effects are not fully established, as follow-up durations were limited in the controlled trials.

For Generalized Anxiety Disorder (GAD), similar RCT designs were applied in studies monitoring measured outcomes. Data show patterns related to the reported outcomes for core psychic and physical symptoms over short periods, typically 10 to 12 weeks. Comparative evidence is lacking against all other similar treatment classes across all outcomes, and data for long-term maintenance of effect is still emerging.


Evidence Researching Chronic Pain Syndromes

For Diabetic Peripheral Neuropathic Pain (DPNP), evidence is derived from multiple short-term placebo-controlled RCTs. These studies monitored reported pain measures, using scales to measure 24-hour average pain severity. Research describes how patients reported their experience over a typical 12-week study period. However, research exploring outcomes beyond this short-term period is limited, and long-term effects are not fully established for pain outcomes.

The medicine was evaluated in studies using RCTs for Fibromyalgia (FM), focusing on outcomes related to systemic or functional imbalance, such as pain severity and functional scales (FIQ). Findings were mixed in some larger-scale trials, meaning not all primary outcomes achieved pre-specified levels of reported change. Evidence quality varies across studies, and data for long-term outcomes for FM beyond six months are typically derived from non-controlled, open-label research scenarios.


Research Gaps and Areas of Uncertainty

Across multiple conditions, there is limited information for long-term outcomes and the durability of reported change, as the most rigorous studies focus on acute, short-term symptom patterns. For conditions like Fibromyalgia, findings suggest that evidence quality varies across studies and that certainty remains low regarding consistent outcomes. Additionally, comparative evidence is lacking against all alternative treatment options for some indications. Research notes that findings apply only to the populations studied, and data for certain groups, such as those under the age of 18 (pediatric populations), remain insufficient for all approved indications.

Key Studies & References Effectiveness of pharmacological therapies for fibromyalgia syndrome in adults: an overview of Cochrane Reviews (Moore et al., 2024)

Frequently Asked Questions (FAQ)

Common questions about Duzela (FAQ)


Q: What conditions is Duzela most commonly prescribed to help manage?

A: The medicine is officially approved for managing several conditions. These include Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), Diabetic Peripheral Neuropathic Pain (DPNP), and the chronic pain condition Fibromyalgia (FM).

Q: How is Duzela used in the management of nerve pain, like diabetic neuropathy?

A: For conditions like diabetic peripheral neuropathy, the drug is used to help manage the associated chronic pain. It achieves this by modulating the transmission of pain signals through the central nervous system, which affects how pain is perceived.

Q: Is there a difference in how Duzela works for pain compared to how it works for mood?

A: Official information describes the drug's mechanism as a dual action on the central nervous system. This dual action involves increasing the availability of the chemical messengers Serotonin and Norepinephrine. This neurochemical potentiation is believed to help manage signals related to both mood and chronic pain perception simultaneously.

Q: Does Duzela work in a similar way to other common anxiety or depression medicines?

A: The medication belongs to a class known as SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors). While some common mood medicines only target one chemical messenger, Serotonin, this drug works by affecting both Serotonin and Norepinephrine. This dual mechanism defines its therapeutic profile.

Q: What is the significance of Duzela being an SNRI?

A: The significance of its SNRI classification is that it provides a dual therapeutic action. Official sources describe this dual action as supporting mood balance while also modulating the nerve pathways responsible for chronic pain signals. This profile is used to address conditions where both factors are present.

Q: What is Serotonin Syndrome, and is it a potential risk with Duzela?

A: Serotonin Syndrome is a potentially serious condition related to an excess of serotonin activity. Regulatory documents state that symptoms may include agitation, confusion, fast heart rate, high blood pressure, sweating, and lack of coordination. This syndrome is a known risk, particularly when the drug is combined with other serotonergic medicines.

Q: How long do common side effects like nausea typically last after starting Duzela?

A: Official product information notes that common side effects, such as nausea, are typically mild to moderate in severity. These effects often decrease in intensity or go away entirely within the first few weeks as the body adjusts to the medication.

Q: Does Duzela have the potential to cause sexual side effects, and are they usually temporary?

A: Official reports confirm that sexual dysfunction is a possible side effect, and this can include issues like delayed or impaired ejaculation. While some effects may resolve, the full duration or complete reversibility of sexual side effects is not universally established in regulatory documentation.

Q: Is weight gain or weight loss a reported side effect of Duzela treatment?

A: Official labeling reports that both weight decrease and weight increase are possible side effects associated with the drug. In some longer-term clinical studies, a trend of initial weight loss followed by a modest weight gain was observed.

Q: What symptoms should prompt a person to seek medical attention quickly regarding Duzela side effects?

A: Regulatory documents state that certain serious symptoms require prompt notification of a healthcare provider. These symptoms include difficulty breathing, swelling of the face or throat, fever, severe skin rash, confusion, or signs of liver problems (such as yellowing of the skin).

Q: Is it normal to feel a sensation of restlessness when first starting Duzela?

A: Official labeling indicates that a sensation of restlessness or agitation is a reported effect. This can sometimes manifest as an inability to sit or stand still (akathisia), particularly when treatment is initiated or following a change in dosage.

Q: How long does it usually take before a person begins to feel the full therapeutic effects of Duzela?

A: Official patient information indicates that it typically takes 2 to 4 weeks before a person begins to feel the initial therapeutic effects for mood disorders. For pain conditions, the necessary adjustment period may sometimes be longer to notice the full benefits.

Q: Does the onset of pain relief from Duzela differ from the onset of mood improvement?

A: Studies suggest that the onset for pain relief may differ from mood improvement. While mood effects are typically observed within 2 to 4 weeks, clinical studies for certain nerve pain conditions often monitor pain measures over 12-week periods, suggesting a potentially longer time frame for adjustment.

Q: How long does Duzela stay in the body after the last dose is taken?

A: The time it takes for half of the drug to be eliminated from the body (the elimination half-life) is reported to be about 12 hours. It generally takes approximately 3 days of regular, continuous dosing to reach a steady concentration in the body.

Q: What is the recommended long-term usage pattern for Duzela?

A: Clinical studies examining effectiveness and safety often have follow-up periods ranging from six months to one year. Official sources indicate there is limited data available regarding the long-term patterns and continued effectiveness of the medicine beyond the periods studied in controlled trials.

Q: What are the signs of "discontinuation syndrome" that are associated with stopping Duzela?

A: Official documentation lists specific signs associated with stopping the medication. These symptoms of discontinuation syndrome may include dizziness, sensory disturbances (such as electric shock sensations), sleep disturbances, nausea, vomiting, anxiety, headache, and agitation.

Q: Does Duzela lose its effectiveness over a long period of time?

A: Official research indicates that the most rigorous studies typically monitor outcomes over acute, short-term periods. Because of this, information on the durability of effect or whether the medicine loses its effectiveness over many years of treatment is limited in the current published data.

Q: Is Duzela generally considered appropriate for elderly patients?

A: Official information suggests that older adult patients may require additional caution during use. This is due to an increased likelihood of certain side effects, such as dizziness, falls, and a potential for low sodium levels (hyponatremia). Official information mentions that a lower starting dose may be used in this population to promote initial adjustment.

Q: Can Duzela be taken at the same time as other common prescription medications?

A: Regulatory documents describe a number of potential interactions when this medication is taken with other prescription drugs. Increased risk is described when combining it with medicines that affect blood clotting or other drugs that increase serotonin levels. It is also known to interact with medicines processed by certain liver enzymes.

Q: Is Duzela a medication that has a potential for dependence or is it considered habit-forming?

A: Official information clarifies that the medication is not scheduled as a controlled substance. However, because of the risk of discontinuation symptoms, regulatory guidelines mandate that the dose must be gradually reduced (tapered) upon cessation of treatment. This requirement indicates that the body can develop a physical reliance on the drug.

Q: Is Duzela the same medication as other branded products containing duloxetine?

A: Duzela is one of the brand names for the active compound, duloxetine hydrochloride. This means the exact same active ingredient may be sold under different brand names or as the generic drug, duloxetine.

Q: What should a person do if they realize they missed a dose of Duzela?

A: Patient information describes a standard protocol: a missed dose is generally taken as soon as it is remembered. If it is almost time for the next scheduled dose, the described protocol is to skip the missed dose entirely and resume the regular schedule. Patient labeling states not to take two doses at the same time.

Q: Can Duzela affect a person's ability to drive or operate machinery?

A: Official labeling states that this medication may cause side effects such as dizziness, drowsiness, or somnolence. These effects may potentially impair a person's judgment, thinking, or motor skills. Regulatory guidance describes the risk of impairment and advises caution regarding driving or operating machinery until the drug's effects are known.

Q: What kind of laboratory tests or medical monitoring might be recommended during Duzela treatment?

A: Official safety information discusses the need to monitor certain health indicators during treatment. This may involve checking blood pressure, screening for a history of bipolar disorder, and monitoring liver function and sodium levels.

Q: Are there any known food or dietary supplements that are contraindicated with Duzela?

A: Official labeling describes that alcohol use is to be avoided due to the increased risk of liver damage. The herbal supplement St. John's Wort is described as presenting a risk of Serotonin Syndrome when combined with this medication.

Q: Is Duzela considered to be a controlled substance?

A: Official classification confirms that this medication is not scheduled as a controlled substance under the regulatory framework of the Controlled Substances Act. It is, however, a prescription-only medication.

How should Duzela be stored and disposed of?

How to Store and Dispose of Duzela

Duzela (duloxetine delayed-release capsules) must be stored according to official regulatory specifications to maintain its stability. Storage requires maintaining the medication at Controlled Room Temperature, defined as 20^circ to 25 C (68^circ to 77 F), with permitted excursions up to 30 C.

Mandatory Storage Rules:

  • The capsules must be stored in their original container and kept tightly closed to protect them from moisture and excessive heat.
  • It is prohibited to freeze the medication.
  • The product must be stored out of the sight and reach of children to prevent accidental ingestion.

Disposal Protocol:

Any unused or expired Duzela must be disposed of according to local regulatory guidelines and the advice of a healthcare professional. Do not keep outdated medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Duzela found in:

A-Z Index: